sar425899 glucagon glp-1 dual agonist sanofi Media Centre-mvanhaasteren.nl The molecular pharmacology of glucagon

Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)

These statements have not been evaluated by the Food and Drug Administration

Learn about GLP-1 agonists, what they can help treat, and how they work to promote weight loss

GLP-1 is a hormone your body makes

Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.

Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News